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 Patient: Male, 48
 Final Diagnosis: Antiphospholipid syndrome
 Symptoms: Chest pain • confusion • seizure-like activity
 Medication: —
 Clinical Procedure: Endovascular venous suction thrombectomy
 Specialty: Hematology
 Objective: Rare disease
 Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by antibodies directed against phos-
pholipids on plasma membranes. Through unclear mechanisms, APS confers hypercoagulability. APS may cause 
recurrent thromboses in the arterial and venous vasculature. We report a case of primary APS resulting in ce-
rebral venous thrombosis and ST-elevation myocardial infarction (STEMI) for which only antiphosphatidylser-
ine (aPS) IgM antibody was positive after extensive investigation.
 Case Report: A 48-year-old male was admitted after a witnessed generalized seizure with subsequent confusion. Imaging 
demonstrated thrombosis of multiple central nervous system (CNS) sinuses, including the superior sagittal si-
nus and bilateral transverse sinuses. The patient was heparinized with aggressive hydration, which proved in-
adequate, prompting endovascular thrombectomy. Three months later, despite anticoagulation therapy, the 
patient developed a STEMI when International Normalized Ratio (INR) was 1.8. Echocardiogram (ECHO) and 
PAN CT scan were normal. Initial coagulation studies demonstrated normal anticardiolipin antibody, prothrom-
bin time, partial thromboplastin time, and platelet count. Outpatient coagulation studies revealed normal an-
tithrombin III, protein C/S, hemoglobin electrophoresis, homocysteine, anti-b2 glycoprotein 1 antibodies, and 
D-Dimer. Factor V Leiden, JAK 2 mutation, prothrombin gene mutation, and tests for paroxysmal nocturnal he-
moglobinuria (PNH) were negative. A positive phosphatidylserine IgM was detected. The patient was contin-
ued on warfarin (10 mg daily) with a target INR of 3.0–3.5 and clopidogrel (75 mg daily).
 Conclusions: Despite extensive investigation, this patient only showed evidence of elevated aPS IgM antibodies, likely con-
tributing to his CNS venous sinus thromboses and STEMI. It is important to screen for antiphosphatidylserine 
antibodies in cases of unprovoked thrombosis when standard thrombophilia analysis is unrevealing. This will 
assist in identifying pathogenicity and help prevent recurrence of subsequent thromboses.
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Background
Antiphospholipid syndrome (APS) is an acquired autoim-
mune disorder that results in a hypercoagulable state char-
acterized by recurrent venous and/or arterial thrombosis [1]. 
Antiphospholipid antibodies are directed against proteins 
that bind to anionic phospholipids on plasma membranes [2]. 
APS can be characterized as a primary or secondary disorder 
and is more frequently seen in women, particularly those who 
have pregnancy-related complications such as miscarriage, 
stillbirth, or preterm delivery [3]. APS may contribute to an 
increased frequency of stroke or myocardial infarction (MI), 
especially in younger individuals [3]. Laboratory classification 
of APS requires the presence of at least one of the following: 
lupus anticoagulant, moderate to high levels of anticardiolip-
in antibodies (aCL), and/or moderate to high levels of anti-b2 
glycoprotein 1 antibodies (Anti-b2GP1) [3]. Anticardiolipin an-
tibody testing should include cardiolipin and b2GP1, as well 
as the individual isotypes IgG, IgM, and IgA. While various risk 
factors can contribute to the formation of a venous thrombo-
embolism (VTE), it is important to keep APS in the differential 
diagnosis, especially when thrombosis is unprovoked. Here, 
we report an uncommon case of primary APS resulting in ce-
rebral venous thrombosis and STEMI, for which only aPS IgM 
antibody was positive after an extensive workup.
Case Report
A 48-year-old white male was taken to the emergency room 
after his family witnessed a generalized seizure and noted sub-
sequent prolonged confusion and agitation in February 2017. 
Glasgow coma scale (GCS) was 13 upon admission. Computed 
tomography (CT), magnetic resonance imaging (MRI), and mag-
netic resonance venography (MRV) demonstrated thrombosis 
of multiple CNS sinuses. MRI demonstrated left temporal lobe 
edema and small linear hemorrhages (Figure 1). MRV and con-
ventional angiography demonstrated cerebral venous throm-
bosis of multiple CNS sinuses including a vertebral artery oc-
clusion of unknown chronicity and bilateral transverse sinus 
thrombosis, as well as straight sinus and superior sagittal si-
nus thrombosis (Figure 2). The patient was placed on leveti-
racetam, systemic heparin, and aggressive hydration without 
difficulty, but suffered progressive clinical worsening requir-
ing endovascular mechanical venous suction thrombectomy, 
resulting in good angiography effect (Figure 3). The initial co-
agulation workup was completed and demonstrated normal 
aCL, prothrombin time (PT), and activated partial thrombo-
plastin time (APTT).
The patient denied any past medical history or surgical history 
prior to the thrombotic event. He denied a history of tobacco 
Figure 1.  Axial FLAIR MRI reveals hyperintensity consistent with 
left temporal lobe edema (arrow) and small linear 
hemorrhages.
Figure 2.  Contrast-enhanced coronal MRV demonstrating 
extensive superior sagittal sinus thrombosis (horizontal 
arrow) affecting the right transverse sinus (vertical 
arrow).
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and illicit drug use. He did report drinking two 12-ounce cans 
of beer per month.
His family history was unremarkable for familial thrombotic 
tendency or autoimmune disease. His maternal uncle report-
edly had polycythemia vera, his paternal grandfather had pros-
tate cancer, and his maternal grandmother had bone cancer.
The patient was discharged 6 days after admission on war-
farin, enoxaparin, and levetiracetam with an appointment to 
follow up with hematology to begin an outpatient thrombo-
philia workup.
While undergoing an outpatient workup, in May 2017, just 
3 months after his initial presentation, he developed burn-
ing retrosternal chest pain with radiation to the left arm. 
An electrocardiogram (EKG) showed sinus rhythm with in-
verted T waves inferiorly, which proved to be a ST-elevation 
myocardial infarction (STEMI); simultaneously, International 
Normalized Ratio (INR) revealed a level of 1.8. Intravenous 
heparin was commenced. Echo showed normal left ventricu-
lar systolic function with middle inferior hypokinesis. Coronary 
angiography indicated evidence of obstructive coronary ar-
tery disease with 50% stenosis in the left circumflex artery, 
30% stenosis in the distal left anterior descending artery, and 
40% stenosis in the proximal left anterior descending artery. 
The patient was discharged 5 days after admission on enoxa-
parin 120 mg subcutaneous injection twice daily, clopidogrel 
75 mg daily, atorvastatin 40 mg daily, and lisinopril 10 mg daily.
At his outpatient hematology follow-up, physical examination 
revealed normal vital signs. He was obese with a body mass 
index (BMI) of 31.4kg/m2.
The neck examination was normal, showing supple without 
lymphadenopathy. The skin examination was normal, with 
no heliotrope rash, malar rash, acrocyanosis, or livedo reticu-
laris. Bilateral heart and lung examination results were normal. 
No carotid bruits were noted. The abdomen was soft, non-
tender, and non-distended with no hepatosplenomegaly. 
The neurological examination was normal. Distal pulses were 
palpable and lower extremities were without edema or cyanosis.
A bilateral lower-extremity venous Doppler was negative. 
A PAN CT scan was done to rule out underlying malignancy 
and was negative.
Laboratory studies included a general hematology analysis, 
which was within normal limits with the exception of a low 
platelet count (120×103/uL), which recovered to 159×103/uL 
within 2 months. Studies showed a white blood cell count of 
6.0×103/uL and a normal hemoglobin of 14.0 g/dL.
His general chemistry results were normal.
Based on past thrombotic and embolic events, despite antico-
agulation therapy, a full hypercoagulability workup was com-
pleted, including protein C, protein S, antithrombin III, factor 
V Leiden, D-dimer, fibrinogen, flow cytometry for paroxysmal 
nocturnal hemoglobinuria (PNH), homocysteine, hemoglobin 
electrophoresis, factor VIII, factor X, complement, plasminogen 
activator inhibitor (PAI) screen, JAK2 mutation detection, pro-
thrombin gene mutation screen, antiphospholipid antibodies, 
and beta-2 glycoprotein 1 antibodies (Table 1). General coag-
ulation tests prior to warfarin initiation showed normal pro-
thrombin time (PT: 10.5 s), International Normalized Ratio (INR) 
1.0, normal activated partial thromboplastin time (APTT: 28.5 s), 
and negative D-dimer of <0.20 mg/L FEU. Protein C, protein S, 
antithrombin III, fibrinogen, homocysteine, complement lev-
els, and hemoglobin electrophoresis were normal. Factor VIII 
activity was just slightly above the normal range, while factor 
X was low. He lacked factor V Leiden and prothrombin gene 
mutation. JAK2 and PAI genotype were normal. Flow cytome-
try was negative for PNH. Cardiolipin antibodies were normal 
(IgG: <9; IgM: 13; IgA: <9). Beta-2 glycoprotein 1 antibodies 
were normal (IgG: <9; IgM: <9; IgA: <9). Of note, his phospha-
tidylserine antibodies (IgM) were significantly positive, with a 
value of 45. Phosphatidylserine antibodies IgG and IgA were 
normal (IgG: 1; IgA: 1).
The patient was continued on clopidogrel (75 mg daily) and 
transitioned from enoxaparin (120 mg, twice per day) to war-
farin (10 mg daily) with a target INR of 3.0–3.5.
Figure 3.  Coronal MRV contrast injection revealing improved 
drainage through superior sagittal sinus (horizontal 
arrow) and transverse sinus (vertical arrow) after 
venous sinus aspiration thrombectomy.
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Discussion
Phosphatidylserine is a negatively charged phospholipid that 
is a component of the cellular membrane. This phospholip-
id acts as a procoagulant when activated by collagen, throm-
bin, or antibodies, resulting in a hypercoagulable state [2]. 
While phosphatidylserine is not the most common antiphos-
pholipid antibody (aPL), it serves as a significant antigenic tar-
get in APS [4]. Antiphospholipid syndrome is characterized by 
a prothrombotic state that can occur in both venous and ar-
terial vasculature [5].
The most common aPLs include lupus anticoagulant, aCL, and 
anti-b2GP1 [4]. These aPLs react with phospholipids and proteins 
on the venous and arterial vasculature, ultimately resulting in 
thrombosis [4]. b2GP1 is the most common of these antibodies 
and is found in the vast majority of seropositive APS patients [4].
The most common sites of thrombosis consist of cerebral ar-
terial vasculature and the lower-extremity venous system [5]. 
The clinical presentation of APS most commonly includes pul-
monary embolism (PE), deep venous thrombosis (DVT), and/or 
thrombosis in the arterial system [3]. The initial presenta-
tion may or may not be associated with dermatologic mani-
festations such as livedo reticularis and a heliotrope rash [3]. 
Result Value/result Units Range
Prothrombin time (PT) 10.5 Seconds 9.1–12.0 
International normalized ratio (INR) 1.0 0.8–1.2 
Partial thromboplastin time (APTT) 28.5 Seconds 24.0–33.0 
Protein C – functional 117 % 73–180 
Protein S, total 120 % 60–150 
Antithrombin III activity 94 % 75–135 
Factor V Leiden mutation Negative Negative
D-Dimer <0.20 mg/L FEU 0.00–0.49 
Fibrinogen 291 mg/dL 193-507
Flow cytometry PNH* No evidence of PNH No evidence of PNH
Homocysteine 11.7 umol/L 0.0–15.0 
Hemoglobin solubility** Negative Negative
Factor VIII activity 168 % 56–163 
Factor X activity 15 % 76–183 
Complement, total 56 U/ml 42–60 
PAI-1 activity 5G/5G***
JAK2 mutation inhibitor Negative Negative
Prothrombin gene mutation Negative Negative
Anticardiolipin Ab, IgG <9 U/ml 0–15
Anticardiolipin Ab, IgM 13 U/ml 0–12
Anticardiolipin Ab, IgA <9 U/ml 0–11
Beta-2 glycoprotein I Ab, IgG <9 GPI IgG units 0–20
Beta-2 glycoprotein I Ab, IgM <9 GPI IgM units 0–32
Beta-2 glycoprotein I Ab, IgA <9 GPI IgA units 0–25
Antiphosphatidylserine IgG 1 GPS IgG 0–11 
Antiphosphatidylserine IgM 45 MPS IgM 0–25 
Antiphosphatidylserine IgA 1 APS IgA 0–20 
Table 1. Hypercoagulability profile.
* Peripheral blood specimen; ** normal adult hemoglobin present; *** homozygous for 5G insertion allele which is associated with the 
lowest PAI-1 activity.
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In women of child bearing age, obstetric complications such 
as miscarriage and stillbirth may be the initial presentation of 
APS [3]. Thrombosis is the most common initial presentation 
and is typically diagnosed by CT, MRI, MRV, or Doppler ultra-
sound to confirm a thrombotic event in the brain, chest, ab-
domen, or deep veins of the lower extremities.
The differential diagnosis when encountering a patient with 
thrombophilia can be extensive. Malignancy may initially pres-
ent with thrombotic tendencies and should be ruled out with 
imaging. Homocystinemia, antithrombin III deficiency, protein 
C or S deficiency, factor V Leiden mutation, and prothrombin 
gene mutation should be considered in patients who exhib-
it thrombophilia [6]. Atherosclerotic vascular disease should 
also be ruled out in patients presenting with prothrombotic 
tendencies. The workup for a hypercoagulable state should 
investigate both inherited and acquired conditions that may 
contribute to a procoagulant state [6].
The diagnosis of APS is primarily based on the detection of an-
tiphospholipid antibodies in a patient’s serum and evidence of 
thrombosis [7]. Triple positivity of lupus anticoagulant, anticar-
diolipin antibodies, and beta-2 glycoprotein 1 antibodies create 
the highest risk of thromboembolic events [7]. Deficiencies in 
protein C, protein S, and antithrombin should be explored, as 
well as mutations, including factor V Leiden, prothrombin, and 
plasminogen inhibitor genes [6]. Antibodies directed against 
phosphatidylserine should also be considered when initial APS 
studies are negative [7]. Recent studies have demonstrated a 
significant association between aPS and APS, and seronega-
tive APS patients have been found to be positive for aPS [8,9].
The mainstay of treatment for thrombotic events associated 
with APS primarily consists of anticoagulation [10]. In certain 
circumstances aspirin and heparin may be used, but warfarin 
is the most commonly prescribed anticoagulant for treatment 
of APS [10]. Recent research emphasizes the importance of in-
definite anticoagulation for patients who have had a throm-
botic event, due to the high recurrence risk [10].
The patient discussed in this case report is a prime example 
of a seronegative APS patient who tested positive only for aPS 
after an extensive thrombophilia workup. This patient did not 
have any significant risk factors that would have contribut-
ed to his thrombophilia. He denied recent hospitalization, im-
mobilization, and smoking, showed no evidence of malignan-
cy, and had no personal or family history of clotting disorders. 
The patient’s mild obesity and positive phosphatidylserine IgM 
were the only apparent contributing factors. Of note, a recent 
case report described multiple etiologies in a lower-extremi-
ty DVT, including significantly positive phosphatidylserine IgG 
antibodies, which demonstrates the importance of this as a 
risk factor for thrombosis [11]. At 1-year follow-up, the patient 
had not developed any autoimmune or collagen vascular dis-
eases. This study suggests further investigation into the pos-
sibility of phosphatidylserine antibodies in individuals with 
clinical symptoms related to thrombosis with an exhaustive, 
unrevealing clinical workup.
Conclusions
It is important to consider other uncommon causes for thrombo-
philia, such as APS. Laboratory testing should include the com-
mon disorders that result in thrombophilia, but if results are un-
revealing, further workup is necessary. Antiphosphatidylserine 
antibodies should be considered if there is a high index of sus-
picion for a hypercoagulable state in patients who have a pan-
negative standard thrombophilia workup.
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